We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Biomarker Candidate for Amyotrophic Lateral Sclerosis Explored

By LabMedica International staff writers
Posted on 23 Dec 2020
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease causing a rapid loss of motor function, which usually results in a serious condition with early death within a few years. More...
So far, early and precise diagnosis of the disease has been difficult.

To date, one of the key challenges in ALS diagnostics is to exclude other mimicking diseases, which are assessed based on clinical and electrophysiological parameters, while disease‐specific diagnostic and prognostic biomarkers are still lacking. In ALS, the TDP-43 protein in particular plays a pivotal role. It forms small inclusions in nerve cells. TDP-43 inclusions appear to have crucial pathomechanistic significance and are the neuropathological markers in sporadic and many genetic ALS cases.

A multidisciplinary team of scientists working with the Ruhr University Bochum (Bochum, Germany) analyzed the secondary structure distribution of TDP‐43 in cerebrospinal fluid of 36 ALS patients compared to 30 Parkinson´s disease patients (PD) and 34 further controls (Ctrl) using the immuno‐infrared sensor technology. The immuno‐infrared sensor is a universal technology that provides a relative measure directly reflecting the secondary structure distribution of a biomarker in a biofluid. The samples are analyzed in a flow‐through system.

The team succeeded in securing a diagnosis of ALS based on the altered structure of the protein TDP-43. In the process, they showed that the proteins fold from predominantly disordered and helical structures to so-called ß-sheets. These shapes promote damage assemblies and deposits of the protein in nerve cells. In the analysis, 36 ALS patients were distinguished from 30 Parkinson's patients by means of the TDP-43 signal with a sensitivity of 89% and a specificity of 77%. In addition, a control group with neurologically inconspicuous patients was differentiated with a sensitivity of 89% and a specificity of 83%. By analyzing TDP-43, the investigators were able to exclude other diseases that affect motor function, such as Parkinson's disease.

Léon Beyer, MSc, one of the lead authors of the study and PhD student at the Prodi Biospectroscopy Department, said, “This achievement may provide new insight into the mechanisms of the disease. Compared to other methods that reflect concentrations of certain proteins, our infrared sensor technology gives insights into molecular events and may therefore become a crucial tool in the future for diagnosing and for developing clinical therapies. First and foremost, however, it will contribute greatly to a more precise understanding of diseases.”

The authors concluded that their findings demonstrate that TDP‐43 misfolding measured by the immuno‐infrared sensor technology has the potential to serve as a biomarker candidate for ALS. The study was published on December 3, 2020 in the journal Annals of Clinical and Translational Neurology.

Related Links:
Ruhr University Bochum


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.